Birt-Hogg-Dubé syndrome in a patient with melanoma and a novel mutation in the FCLN gene

International Journal of Dermatology

Volumn 52, Issue 3, 2013, Pages 323-326

  Mota Burgos, Ana ^a   Acosta, Enrique Herrera ^a   Márquez, Francisco Vílchez ^a   Mendiola, Matilde ^a   Herrera Ceballos, Enrique ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRONE;

ADULT; ARTICLE; BIRT HOGG DUBE SYNDROME; CASE REPORT; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MELANOMA; PHYSICAL EXAMINATION; SENTINEL LYMPH NODE BIOPSY;

BIRT-HOGG-DUBE SYNDROME; EXONS; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84873944597     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.05742.x     Document Type: Article

References (17)

1. Welsch MJ, Krunic A, Medenica MM. Birt-Hogg-Dubé syndrome. Int J Dermatol 2005; 44: 668-673.
2. De la Torre C, Ocampo C, Doval IG, et al. Acrochordons are not a component of the Birt-Hogg-Dubé syndrome: does this syndrome exist? Case reports and review of the literature. Am J Dermatopathol 1999; 21: 369-374.
3. Vincent A, Farley M, Chan E, et al. Birt-Hogg-Dubé syndrome: a review of the literature and the differential diagnosis of firm facial papules. J Am Acad Dermatol 2003; 49: 698-705.
4. Chung JY, Ramos-Caro FA, Beers B, et al. Multiple lipomas, angiolipomas, and parathyroid adenomas in a patient with Birt-Hogg-Dubé syndrome. Int J Dermatol 1996; 35: 365-367.
5. Toro JR, Glenn G, Duray P, et al. Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. Arch Dermatol 1999; 135: 1195-1202.
6. Schaffer JV, Gohara MA, McNiff JM, et al. Multiple facial angiofibromas: a cutaneous manifestation of Birt-Hogg-Dubé syndrome. J Am Acad Dermatol 2005; 53: 108-111.
7. Pavlovich CP, Grubb RL, Hurley K, et al. Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol 2005; 173: 1482-1486.
8. Zbar B, Alvord WG, Glenn G, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev 2002; 11: 393-400.
9. Khoo SK, Giraud S, Kahnoski K, et al. Clinical and genetic studies of Birt-Hogg-Dubé syndrome. J Med Genet 2002; 39: 906-912.
10. Sempau L, Ruiz I, González-Morán A, et al. Nueva mutación en el síndrome de Birt-Hogg-Dubé. Actas Dermosifiliogr 2010; 101: 637-640.
11. Cocciolone RA, Crotty KA, Andrews L, et al. Multiple desmoplastic melanomas in Birt-Hogg-Dubé syndrome and a proposed signaling link between folliculin, the mTOR pathway, and melanoma susceptibility. Arch Dermatol 2010; 146: 1316-1318.
12. Toro JR, Wei MH, Glenn GM, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet 2008; 45: 321-331.
13. Wei MH, Blake PW, Shevchenko J, Toro JR. The folliculin mutation database: an online database of mutations associated with Birt-Hogg-Dubé syndrome. Human Mutat 2009; 30: 880-890.
14. Lindor NM, Hand J, Burch PA, et al. Birt-Hogg-Dubé syndrome: an autosomal dominant disorder with predisposition to cancers of the kidney, fibrofolliculomas, and focal cutaneous mucinosis. Int J Dermatol 2001; 40: 653-656.
15. Takagi Y, Kobayashi T, Shiono M, et al. Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein. Oncogene 2008; 27: 5339-5347.
16. Karbowniczek M, Spittle CS, Morrison T, et al. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008; 128: 980-987.
17. Meier F, Guenova E, Clasen S, et al. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. J Am Acad Dermatol 2009; 60: 863-868.